Dr. John Cush RheumNow
1 month 3 weeks ago
EULAR 2026 Daily Recap LIVE
By Day 3, the biggest stories of EULAR begin to emerge.
Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty for a fast-paced review of the studies, debates, and breakthrough findings that rheumatologists will be discussing long after the meeting https://t.co/7hvwCkUz9C
The clinical abstract sessions on diagnostic tools in lupus showcased interesting studies, including the use of MRI as potential non-invasive biomarkers.
Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an impact on our practice? Here is my selection of 3 abstracts presented at EULAR 2026 that identify therapeutic strategies that are well worth keeping on our radar.
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
💉Do GLP-1 agonists improve DMARD persistence in PsA/axSpA?
TriNetX real-world study (n=3,068): YES!
Better b/tsDMARD persistence and lower stroke & mortality risk
#POS0194 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage?
Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males
#POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients?
Data from the RABBIT-SpA registry (n=2,236) confirms:
67% vs 73% with 2009 criteria
Clinical arm rarely fulfilled
#POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
🔍 Do posterior element lesions progress over 10 years in axSpA?
Data from the DESIR inception cohort (n=320) says RARELY!
But baseline PE inflammation raises facet ankylosis risk ~70-fold
#POS0189 #EULAR2026 @RheumNow https://t.co/PdwlPGjKqK
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
🔮 Can polygenic risk scores predict PsA timing in psoriasis?
Another GWAS study (n=703) says YES!
70-SNP model achieves AUC 0.843 for predicting PsA onset <10 vs >10 years
#POS0088 #EULAR2026 @RheumNow https://t.co/wI4Jy8Yu2A
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
🧪 Can genetics predict TNFi response in PsA?
OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months
#POS0087 #EULAR2026 @rheumnow
Antoni Chan MD (Prof) synovialjoints
1 month 3 weeks ago
CyTOF reveals significant sexual dimorphism in monocyte populations in active #axSpA
Women show reduced classical and non-classical monocytes vs healthy controls. Men do not show the same pattern.
Sex is not just a demographic variable in AxSpA it is also an immunological one.
Dr. John Cush RheumNow
1 month 3 weeks ago
From Skepticism to Reconsideration: 4‑Year CAR‑T Outcomes in Lupus
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed https://t.co/Dmmw90XnuF
Dr. John Cush RheumNow
1 month 3 weeks ago
DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6
Dr. John Cush RheumNow
1 month 3 weeks ago
Progress of biologics/targeted therapy in SLE
We are in a transformative era for SLE, for clinicians and patients. Four targeted therapies are now licensed: belimumab (nephritis and non‑renal), voclosporin and obinutuzumab (nephritis), and anifrolumab (non‑renal). Many agents https://t.co/BuFCmj1hQd
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
@RheumNow HOT #Obesity session (7)
📢A call for action
Current RMD treatments ignore obesity:
They all target immune response but miss the metabolic-inflammatory loop
Breaking that cycle may be the missing piece
Obesity must be part of every rheumatology plan
#EULAR2026 @rheumnow
